Table 4 Treatment-emergent adverse events resulting in death*
Cause of death, n (%)a | Ruxolitinib randomized (n = 155) | After ruxolitinib crossoverb (n = 111) | During placebo treatment (n = 151) |
|---|---|---|---|
Death caused by any treatment-emergent adverse event | 28 (18.1) | 28 (25.2) | 11 (7.3) |
Sepsis | 4 (2.6) | 2 (1.8) | 1 (0.7) |
Disease progression | 3 (1.9) | 4 (3.6) | 3 (2.0) |
Pneumonia | 3 (1.9) | 1 (0.9) | 1 (0.7) |
Acute myeloid leukemia | 2 (1.3) | 3 (2.7) | 0 |
Cerebral hemorrhage | 2 (1.3) | 1 (0.9) | 1 (0.7) |
Septic shock | 2 (1.3) | 2 (1.8) | 0 |
Acute renal failure | 1 (0.6) | 1 (0.9) | 0 |
Anemia | 1 (0.6) | 0 | 0 |
Cardiac arrest | 1 (0.6) | 0 | 0 |
Death, unspecified | 1 (0.6) | 1 (0.9) | 0 |
Falling injury | 1 (0.6) | 0 | 0 |
Hemorrhagic shock | 1 (0.6) | 1 (0.9) | 0 |
Metastatic NSCLC | 1 (0.6) | 0 | 0 |
Multiorgan failure | 1 (0.6) | 0 | 1 (0.7) |
Muscular weakness | 1 (0.6) | 0 | 0 |
Myocardial infarction | 1 (0.6) | 1 (0.9) | 0 |
Pancreatic carcinoma | 1 (0.6) | 0 | 0 |
Renal failure | 1 (0.6) | 0 | 0 |
Respiratory failure | 1 (0.6) | 0 | 0 |
Splenic infarction | 1 (0.6) | 0 | 0 |
Congestive cardiac failure | 0 | 2 (1.8) | 0 |
Myelofibrosis | 0 | 2 (1.8) | 1 (0.7) |
Cardiac failure | 0 | 1 (0.9) | 0 |
Pneumonia aspiration | 0 | 2 (1.8) | 0 |
Anastomotic hemorrhage | 0 | 1 (0.9) | 0 |
Cholecystitis | 0 | 1 (0.9) | 0 |
Delirium | 0 | 1 (0.9) | 0 |
Road traffic accident | 0 | 1 (0.9) | 0 |
Splenic rupture | 0 | 1 (0.9) | 0 |
Suicide | 0 | 1 (0.9) | 0 |
Gastrointestinal hemorrhage | 0 | 0 | 1 (0.7) |
Intestinal perforation | 0 | 0 | 1 (0.7) |
Staphylococcal infection | 0 | 0 | 1 (0.7) |